On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company BMY, which announced $4 billion aggregate accelerated share repurchase agreements.
Bristol Myers Squibb recently said that its second-quarter revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio. Analysts estimated sales of $11.81 billion.
Jenny Harrington of Gilman Hill Asset Management named NNN REIT, Inc. NNN, which announced earnings last week. The company has a 5.6% dividend yield.
NNN REIT recently priced its public offering of $500 million of 5.600% senior unsecured notes due 2033.
Analysts have a consensus Buy rating on NNN REIT, according to Benzinga's analyst ratings data.
Josh Brown of Ritholtz Wealth Management said Toast, Inc. TOST had a bunch of price-target hikes on the Street following the earnings release. "I am staying long," he added.
Toast reported mixed second-quarter financial results and issued guidance above estimates.
Don’t forget to check out our premarket coverage here
Price Action: Toast shares fell 1.8% to settle at $22.77, while NNN REIT shares slipped 0.1% to close at $39.96 on Thursday. Bristol-Myers Squibb shares gained 1.1% to $61.29 on Thursday.
Check This Out: Fear & Greed Index Remains In 'Greed' Zone Following Inflation Data
Photo: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.